Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-06-20 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the grant of stock options to employees. It details the number of options granted, the exercise price, and the vesting schedule. There are no financial statements or comprehensive financial data presented. The document is an announcement related to employee stock options, which is a capital-related update but not a full capital structure change or share issue announcement. Given the nature of the disclosure and the regulatory reference, this fits best under Capital/Financing Update (CAP). The document length is short and it is not a report or a certification, so it is not RNS or RPA. Therefore, the classification is CAP with high confidence.
2025-06-20 English
Intimation regarding grant of 2926 stock options under Lupin Employees Stock Option Plans.
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the grant of stock options to employees. It details the number of options granted, the exercise price, and the vesting schedule. The document is addressed to stock exchanges and signed by the Company Secretary and Compliance Officer. It is a regulatory announcement about stock option grants, which falls under capital or financing updates rather than a full report or financial statement. The document length is short (2360 characters), and it is not an annual or interim report, nor an earnings release or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-06-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, informing about the company's participation in an upcoming analyst/institutional investor meet. It mentions the date, organizer, mode, and nature of the meeting but does not contain any financial data, presentation content, or detailed report. The document is only an announcement of a future event and references that any presentation will be in line with what is already available on the company website. The length is only 2042 characters, which is quite short and consistent with an announcement rather than a full report or presentation. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-06-19 English
Intimation about participating in the Analyst/Institutional Investors Meet.
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, informing about the company's participation in an upcoming Analyst/Institutional Investors Meet. It mentions the date, organizer, mode, and nature of the meeting, and notes that any presentation will be in line with what is already available on the company or stock exchange websites. The document is short (2042 characters) and does not contain any financial data, results, or detailed presentations itself. It is essentially an announcement about an investor meeting, not the meeting materials or a report. Therefore, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-19 English
Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a license and supply agreement between Lupin Limited and Sino Universal Pharmaceuticals for commercialization of a pharmaceutical product in China. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on a business partnership and product commercialization, with no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. It is not a report itself but an announcement of a corporate development. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant business agreement impacting the company's commercial operations and potential revenue streams.
2025-06-16 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a license and supply agreement between Lupin Limited and Sino Universal Pharmaceuticals for commercialization of a pharmaceutical product in China. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on a business partnership and product commercialization, with no financial statements, regulatory filings, or detailed financial data. The document length is 6296 characters, which is relatively short and typical for a press release. It does not contain financial results, management discussion, or audit information. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into more specific categories like Capital/Financing Update or M&A Activity, as it is a licensing agreement announcement rather than a merger or financing event.
2025-06-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.